| Document |
Document Title |
|
WO/2024/066026A1 |
Provided is a chimeric antigen receptor targeting IL13Rα2, comprising: (1) an optimized anti-IL13Rα2 scFv sequence; (2) an optimized hinge region/spacer region; (3) a transmembrane region (TM); (4) a CD28 costimulatory domain and a 4-1...
|
|
WO/2024/071397A1 |
The present invention provides an IL13RA2-targeting herpes simplex virus in which an anti-IL13RA2 antibody or an antigen-binding fragment thereof is presented on the viral surface. Also provided is an anti-IL13RA2 antibody or an antigen-...
|
|
WO/2024/072897A1 |
Provided herein are methods, compositions, reaction mixtures, kits and systems for measuring protease activities, detecting protein-protein interactions, and identifying signaling molecules that induce protein-protein interactions. In pa...
|
|
WO/2024/065297A1 |
Embodiments of the present invention provide a chimeric antigen receptor with a light chain variable region having a sequence set forth in SEQ ID NO: 1 and a heavy chain variable region having a sequence set forth in SEQ ID NO: 2. The ch...
|
|
WO/2024/067821A1 |
Provided is a modified cell, wherein the modified cell is formed by binding a complex protein to a cell surface marker molecule of the modified cell. The complex protein comprises a part specifically binding to the cell surface marker mo...
|
|
WO/2024/067401A1 |
The present invention relates to an ultra-long-acting platform for improving the half-life of an active molecule of a drug, which comprises immunoglobulin Fc and an advanced fatty acid chain. The present invention also relates to prepara...
|
|
WO/2024/065268A1 |
Provided is a single-domain antibody or antigen-binding fragment capable of identifying ANG-2, and a multispecific antibody. The antibody or antigen-binding fragment has a heavy chain variable region as represented by any one of SEQ ID N...
|
|
WO/2024/066416A1 |
Provided are a CXCL-BPI fusion protein capable of being used for treating gram-negative bacterial infections, an encoding nucleic acid thereof, an expression and preparation method therefor, and use thereof for preparing a pharmaceutical...
|
|
WO/2024/067725A1 |
Provided are a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer of the recombinant F protein, and an immunogenic compo...
|
|
WO/2024/066377A1 |
The present invention provides a VEGF and ANG-2 bispecific antibody and use thereof. The bispecific antibody comprises: a first binding region, the first binding region comprising a single-chain antibody, and the single-chain antibody ha...
|
|
WO/2024/066616A1 |
Provided is a high-affinity PD1 protein conjugate, which comprises an elastin-like polypeptide and a high-affinity PD1 protein connected to the elastin-like polypeptide. The conjugate significantly improves the biological half-life and b...
|
|
WO/2024/067785A1 |
Provided is use for the treatment of chronic hepatitis B based on an interferon synergistic immune checkpoint blocking antibody. Specifically, provided is a fusion protein, comprising a PDL1-binding polypeptide and an interferon IFN whic...
|
|
WO/2024/072224A2 |
The present invention relates to a peptide-based compound for complexing and stabilizing a double stranded oligonucleotide, the compound comprising a structure p-x-b-x'-p'; wherein: i. p and p' each refer to an oligonucleotide-binding mo...
|
|
WO/2024/069240A2 |
Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in co...
|
|
WO/2024/067451A1 |
The present invention provides an engineered extracellular vesicle, a pharmaceutical composition containing the engineered extracellular vesicle and a use thereof, and further provides a method for constructing the engineered extracellul...
|
|
WO/2024/071409A1 |
Provided are: a nucleic acid complex composition that has high efficiency for introducing nucleic acid molecules into cells and for diffusing the same within the cells and that can have high transfection efficiency; lipid particles for t...
|
|
WO/2024/067723A1 |
A respiratory syncytial virus subtype A (RSV-A) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer formed by the recombinant F protein, an immunogenic composition com...
|
|
WO/2024/072958A1 |
The present invention relates to engineering synthetic major histocompatibility complex (MHC) molecules for generating universal peptide/MHC complexes with engineered disulfide linkage(s) using structure-guided modeling and design and me...
|
|
WO/2024/067670A1 |
The present application relates to an antibody and a conjugate, comprising a variable antigen-binding domain (VHH) of a heavy-chain antibody, wherein the VHH comprises one or more pairs of modified cysteine residues, wherein each pair of...
|
|
WO/2024/071043A1 |
Provided is a novel production method of a hetero that enables the production of a heteromultimeric protein such as a bispecific antibody. The production method of the present disclosure, which is for producing a heteromultimeric prote...
|
|
WO/2024/064910A1 |
This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.
|
|
WO/2024/060424A1 |
Disclosed are a CAR-T cell secreting BiTE and use thereof, and particularly disclosed is a chimeric antigen receptor secreting BiTE. The chimeric antigen receptor comprises a leader peptide, a nanobody targeting mesothelin, an extracellu...
|
|
WO/2024/061239A1 |
Provided are a fusion protein for preventing or treating coronavirus infection, a Spike protein nanoparticle, and a preparation thereof. The fusion protein comprises a mutation-containing coronavirus Spike protein extracellular domain wh...
|
|
WO/2023/024609A9 |
Disclosed in the present invention are an adjuvant for a novel coronavirus COVID-19 vaccine, and a developed bivalent vaccine thereof which contains antigens of a novel coronavirus epidemic HuB strain and a South African mutant strain B....
|
|
WO/2024/064756A1 |
Disclosed are bispecific modulators. Bispecific modulators can bind to a protein of interest and to an internalizing receptor on a cell surface. Once bound, the protein of interest can be internalized and/or degraded inside a cell.
|
|
WO/2024/064309A1 |
A method for selectively isolating lower immunogenic biomolecule-polymer conjugates from an initial source of biomolecule-polymer conjugate, the method comprising eluting the initial source of biomolecule-polymer conjugate through a hydr...
|
|
WO/2024/060948A1 |
The present invention relates to a T cell receptor (TCR) specifically binding to a human papillomavirus E7, a nucleic acid encoding the TCR, an engineered cell comprising same, and a method for preparing the engineered cell. The present ...
|
|
WO/2024/060577A1 |
The present invention relates to an armored CAR-T cell expressing interleukin 15 receptor α and interleukin 15 and immunotherapeutic use thereof.
|
|
WO/2024/060422A1 |
Disclosed are a double-targeting CAR-T cell targeting mesothelin and an NKG2D ligand and use thereof, and particularly disclosed is a chimeric antigen receptor, which comprises a nanobody targeting mesothelin and a protein targeting an N...
|
|
WO/2024/064754A1 |
Disclosed are bispecific modulators that include a therapeutic agent. Embodiments include bispecific modulators conjugated to therapeutic agents. Bispecific modulators can bind to a protein of interest and to an internalizing receptor on...
|
|
WO/2024/061188A1 |
The present invention provides a coronavirus multivalent vaccine and use thereof. The coronavirus multivalent vaccine comprises a coronavirus Spike protein extracellular domain containing a mutation, a truncated fragment thereof, or a fu...
|
|
WO/2024/060167A1 |
The present invention provides a fusion protein, which comprises: a tissue plasminogen activator or a variant thereof; a disintegrin or a variant thereof; and a connector. The connector connects the tissue plasminogen activator or the va...
|
|
WO/2024/061223A1 |
Provided are an antibody and use thereof in resisting a tumor. Provided are a single-domain antibody capable of specifically binding to 4-1BB or an antigen-binding fragment thereof, and a multi-specific antibody. The antibody has improve...
|
|
WO/2024/061306A1 |
The present application discloses antibodies and antibody derivatives that bind to B7H3 (also known as CD276) and methods of using the same. The antibodies or antibody derivatives comprise a single domain antibody that binds to B7H3.
|
|
WO/2024/061061A1 |
Disclosed are a C-type single-domain antibody for neutralizing a novel coronavirus and use thereof. The C-type single-domain antibody of the present invention can inhibit the novel coronavirus (SARS-CoV-2) from invading cells, and is use...
|
|
WO/2024/064261A1 |
Embodiments of the present disclosure pertain to modified cells that include a fusion protein of NPC intracellular cholesterol transporter 2 protein (NPC2) and another protein. Additional embodiments of the present disclosure pertain to ...
|
|
WO/2024/060140A1 |
The present invention relates to a novel chimeric antigen receptor specifically binding to EGFRvIII and use thereof.
|
|
WO/2024/058178A1 |
The present invention provides a reagent that is for measuring an epidermal growth factor receptor tyrosine kinase activity and that contains: a modified polypeptide to which an acceptor and a donor inducing Förster resonance energy tra...
|
|
WO/2024/058155A1 |
The present invention addresses the problem of providing a new method for simply and efficiently producing linear covalently closed DNA. Provided is a double stranded circular DNA vector, wherein the double stranded circular DNA vector...
|
|
WO/2024/055457A1 |
Provided is the use of a JWA polypeptide in the preparation of an anti-Parkinson's disease drug. The amino acid sequence of the polypeptide is as shown in I or II: I: FPG SDRF-Z; II: X-FPGSDRF-Z, wherein amino acid S is subjected to phos...
|
|
WO/2024/059264A1 |
Described herein are compositions and methods for producing immune cells, such as regulatory T cells (Tregs), expressing a chimeric antigen receptor (CAR) which responds to a non-degradable engineered polymeric antigen in a site-specific...
|
|
WO/2024/056028A1 |
Provided are analgesic peptides. Also provided is a formulation comprising any one of the analgesic peptides and a pharmaceutically acceptable excipient. Also provided is a method for treating or preventing pain in a subject in need ther...
|
|
WO/2024/057094A2 |
Human interleukin-2 (IL-2) muteins or variants thereof are provided. Also provided are pharmaceutical compositions that include such IL-2 muteins.
|
|
WO/2024/055995A1 |
Provided are an anti-VEGFA fusion protein, and a preparation method therefor and the use thereof. The anti-VEGFA fusion protein has a high affinity with VEGFA, can effectively block the binding of VEGFA to receptor VEGFR, block a VEGFA s...
|
|
WO/2024/056098A1 |
Provided are an NK cell adapter molecule targeting an NKG2D ligand and an NKp46 and the use thereof. The cell adapter molecule at least comprises: a first binding domain comprising an NKG2D extracellular domain that can specifically bind...
|
|
WO/2024/053630A1 |
The present disclosure provides a new carrier peptide fragment having cell membrane permeability. The disclosed carrier peptide fragment comprises the following amino acid sequence: RKLAVYWSTYKRSR (SEQ ID NO: 1).
|
|
WO/2024/051751A1 |
Disclosed herein are anti-CD123 nanobodies, a chimeric antigen receptor, and use thereof. The nanobodies are VHH01 and VHH02. The nanobodies VHH01 and VHH02 both have good affinity and specificity for CD123. A chimeric antigen receptor a...
|
|
WO/2024/055002A1 |
Provided are a fusion protein comprising a mutated kinetochore protein and dCas9. The fusion protein is used in conjunction with guide RNAs target the fusion protein to a location of kinetochore assembly on a centromere such that the fus...
|
|
WO/2024/051802A1 |
Provided are a GIPR antibody, a fusion protein thereof with FGF21, a pharmaceutical composition thereof, and use thereof. Further provided is a method of the GIPR antibody and the fusion protein thereof with FGF21 for treating, preventin...
|
|
WO/2024/051817A1 |
The present invention relates to a tumor-targeted fusion protein type medicament precursor taking interleukin 2 as an active ingredient.
|
